Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Clinical trial NCT03037385 · COMPLETED

Trial details

NCT number: NCT03037385
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

RET-altered Non Small Cell Lung Cancer Medullary Thyroid Cancer RET-altered Papillary Thyroid Cancer RET-altered Colon Cancer RET-altered Solid Tumors Lung Neoplasm Carcinoma, Non-Small-Cell Lung Thyroid Diseases Thyroid Neoplasm Thyroid Cancer, Papillary Carcinoma, Neuroendocrine Respiratory Tract Neoplasms

Start date: 2017-03-17
Primary completion: 2024-03-21
Enrollment: 590

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.